Journal article
Pharmacogenomics of antimicrobial agents
Pharmacogenomics, Vol.15(15), pp.1903-1930
2014
Abstract
Antimicrobial efficacy and toxicity varies between individuals owing to multiple factors. Genetic variants that affect drug-metabolizing enzymes may influence antimicrobial pharmacokinetics and pharmacodynamics, thereby determining efficacy and/or toxicity. In addition, many severe immune-mediated reactions have been associated with HLA class I and class II genes. In the last two decades, understanding of pharmacogenomic factors that influence antimicrobial efficacy and toxicity has rapidly evolved, leading to translational success such as the routine use of HLA-B*57:01 screening to prevent abacavir hypersensitivity reactions. This article examines recent advances in the field of antimicrobial pharmacogenomics that potentially affect treatment efficacy and toxicity, and challenges that exist between pharmacogenomic discovery and translation into clinical use.
Details
- Title
- Pharmacogenomics of antimicrobial agents
- Authors/Creators
- A.K. Aung (Author/Creator) - The Alfred HospitalD.W. Haas (Author/Creator) - Vanderbilt UniversityT. Hulgan (Author/Creator) - Vanderbilt UniversityE.J. Phillips (Author/Creator) - Murdoch University
- Publication Details
- Pharmacogenomics, Vol.15(15), pp.1903-1930
- Publisher
- Ashley Publications Ltd.
- Identifiers
- 991005540946707891
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
Metrics
140 Record Views